Premium
NY‐ESO‐1 expression is tightly linked to TMPRSS2–ERG fusion in prostate cancer
Author(s) -
Grupp Katharina,
OspinaKlinck Daniel,
Tsourlakis Maria Christina,
Koop Christina,
Wilczak Waldemar,
Adam Meike,
Simon Ronald,
Sauter Guido,
Izbicki Jakob Robert,
Graefen Markus,
Huland Hartwig,
Steurer Stefan,
Schlomm Thorsten,
Minner Sarah,
Quaas Alexander
Publication year - 2014
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.22816
Subject(s) - tmprss2 , pten , prostate cancer , erg , medicine , prostate , tissue microarray , immunohistochemistry , cancer , biochemical recurrence , fusion gene , oncology , cancer research , prostatectomy , biology , gene , apoptosis , pi3k/akt/mtor pathway , genetics , ophthalmology , retinal , disease , covid-19 , infectious disease (medical specialty)
BACKGROUND NY‐ESO‐1 has been suggested as therapeutic cancer vaccine in prostate cancer. This study was undertaken to explore the relationship of NY‐ESO‐1 with tumor phenotype, biochemical recurrence, and molecular subgroups in hormone‐naive prostate cancers. METHODS NY‐ESO‐1 immunohistochemistry was analyzed on a tissue microarray containing 11,152 prostate cancer samples. Results were compared to clinically follow‐up data, ERG status, and deletions on PTEN , 3p13, 5q21, and 6q15. RESULTS NY‐ESO‐1 expression was absent in benign prostate glands. In prostate cancer, NY‐ESO‐1 positivity was found 8.8% of our 8,761 interpretable tumors including 5.8% with weak, 2.5% with moderate, and 0.5% with strong expression. There was a threefold higher rate of NY‐ESO‐1 expression in ERG fusion positive tumors than in ERG negative cancers ( P < 0.0001). There was a significant association with early PSA recurrence, which was largely limited to ERG positive cancers. Within the ERG positive subgroup, high NY‐ESO‐1 expression was associated with early biochemical recurrence ( P = 0.0002) and high Gleason grade ( P < 0.0001). In ERG negative cancers, NY‐ESO‐1 expression was also linked to PTEN ( P = 0.0012) and 6q15 deletions ( P = 0.0005). CONCLUSIONS Our observations indicate a tight link of NY‐ESO‐1 expression to ERG activation and (to a lesser extent) PTEN ‐ and 6q15‐deletions in prostate cancer. The impact of these interactions on the likelihood of response to immunotherapy is unclear. The prognostic impact of NY‐ESO‐1 expression is little and not independent of histologic variables. Prostate 74:1012–1022, 2014 . © 2014 Wiley Periodicals, Inc.